New Biomarkers to Predict the Evolution of In Situ Breast Cancers

Table 2

Expression of different markers in tumor cells and stroma in relapsed and nonrelapsed patients.

Markers	Overall series			G1 + G2			G3
	Nonrelapsed; (median, range)	Relapsed; (median, range)	P	Nonrelapsed; (n = 17); (median, range)	Relapsed; (n = 6); (median, range)	P	Nonrelapsed; (n = 15); (median, range)	Relapsed; (n = 6); (median, range)	P
TG2
Tumor cells	15 (0–100)	3 (0–80)	0.306	20 (0–100)	11.5 (0–70)	0.532	10 (0–70)	2.5 (0–80)	0.463
Stroma	100 (0–100)	100 (70–100)	0.413	100 (20–100)	100 (70–100)	0.929	100 (0–100)	100 (100-100)	0.206
HJURP
Tumor cells	3 (0–90)	8 (0–100)	0.555	2 (0–90)	80 (0–100)	0.063	10 (0–80)	0 (0–70)	0.192
Stroma	0 (0–70)	0 (0–80)	0.347	0 (0–70)	55 (0–80)	0.031	0 (0–70)	0 (0–3)	0.225
HIF-1α
Tumor cells	0 (0–10)	1 (0–70)	0.137	0 (0–10)	0 (0-0)	0.439	0 (0–10)	7.5 (2–70)	0.024
Stroma	0 (0–2)	0 (0–10)	0.096	0 (0–2)	0 (0–10)	0.753	0 (0–2)	2 (0–10)	0.019